If you have primary sclerosing cholangitis, you may be eligible for the SPRING study which aims to improve liver function and could offer relief to PSC-related signs and symptoms.
You may be able to participate in the SPRING clinical study if you:
Are between 18 to 75 years old
Have a confirmed diagnosis of PSC for at least 6 months
Have taken PSC medication and are on a stable dosage for at least 12 weeks
Have high alkaline phosphatase (ALP) blood levels. “High” can be defined at 1.5 times the upper limits of normal (ULN)
For patients with inflammatory bowel disease (IBD)*, it must be mild or in remission
By enrolling in this study, you may receive:
You could potentially see improvement in your overall liver health and potential relief for some of your symptoms.
Your participation in this study may help to advance research and understanding of PSC.
You could potentially see improvement in your liver function and relief to your symptoms in the following ways:
Your participation in this study may help to advance research and understanding of PSC.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare diseases and expertise in navigating the enrollment process, we're here for you every step of the way. To learn more, visit patientwing.com.
